我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

拉西地平对AVP诱导的大鼠心脏成纤维细胞增殖的影响及其与ERK1/2的关系(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2008年第2期
页码:
132-135
栏目:
基础研究
出版日期:
2008-03-20

文章信息/Info

Title:
Effects of lacidipine on cell proliferation of CFs induced by AVP and its relationship with ERK1/2
作者:
陆小龙; 赵连友; 郑强荪; 赵小燕; 何艳萍; 刘慧; 尚福军
第四军医大学唐都医院心内科，陕西 西安 710038
Author(s):
LU Xiaolong;  ZHAO Lianyou;  ZHENG Qiangsun; ZHAO Xiaoyan;  HE Yanping;  LIU Hui;  SHANG Fujun
Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, Shaanxi, China
关键词:
血管加压素; 拉西地平; 心脏成纤维细胞; 增殖; ERK1/2; 大鼠
Keywords:
vasopressin;  lacidipine;  cardiac fibroblasts; proliferation; ERK1/2; rats
分类号:
R972
DOI:
-
文献标识码:
A
摘要:
目的 观察拉西地平对血管加压素（AVP）诱导的大鼠心脏成纤维细胞(CFs)增殖的影响及其与细胞外信号调节激酶（ERK）1/2的关系。方法 以培养的新生SD大鼠CFs为实验模型，采用四氮唑盐比色法测定细胞数目；用流式细胞术分析细胞周期；用蛋白免疫印迹法测定总细胞外信号调节激酶（tERK）1/2和磷酸化细胞外信号调节激酶（pERK）1/2在细胞内的表达。实验按照给予CFs干预因素的不同，分为对照组、10-7mol/L AVP处理组、10-9~10-6 mol/L拉西地平+10-7mol/L AVP干预组和10-7mol/L拉西地平单独干预组。 结果 ①10-7mol/L AVP干预24 h后，CFs的A490值(0.232±0.013)较对照组(0.132±0.008)显著增高(P<0.01)。在10-9~10-6 mol/L拉西地平和10-7mol/L AVP共同干预下，拉西地平可呈浓度依赖性地下调CFs的A490值，分别为0.216±0.01、0.203±0.01、0.176±0.01和0.160±0.01，均显著低于AVP组(P<0.01)。②细胞周期分析显示，AVP组CFs 在S期的百分率和增殖指数(PI)分别为13.06±0.83和21.70±1.55，与对照组(分别为4.60±0.60和8.97±1.56)比较显著增高(P<0.01)。在10-7mol/L 拉西地平干预下，细胞在S期的百分率(8.84±0.80)和PI (15.46±1.84)较AVP组显著降低 (P<0.01)。 ③AVP组CFs的pERK1/2表达显著高于对照组(P<0.01)，10-9、10-8、10-7和10-6mol/L拉西地平组CFs中pERK1/2的表达与AVP组比较呈浓度依赖性地降低(P<0.01)。 结论 拉西地平可抑制AVP诱导的大鼠CFs增殖，提示拉西地平对预防和逆转心脏重构具有一定的作用，其机制可能与ERK1/2的磷酸化有关。
Abstract:
AIM To study the effect of Lacidipine on cell proliferation of cardiac fibroblasts (CFs) induced by vasopressin (AVP) and its relationship with ERK1/2. METHODS CFs were isolated and cultured from neonatal SD rats and the CFs were divided into four groups: control group, 10-7mol/L AVP group, 10-9-10-6 mol/L Lacidipine+10-7mol/L AVP group and 10-7mol/L Lacidipine group. Cell number and cell cycle were evaluated by MTT assay (A value) and flow cytometry technique and Western blot was used to study the protein expression level of tERK1／2 and pERK1／2. RESULTS ①10-7mol/L AVP significantly increased A value of CFs (0.232±0.013) in comparison with that in control group (0.132±0.008,P<0.01). Lacidipine in the range of 10-9-10-6 mol/L attenuated the A value of AVP group in a concentration dependent manner (0.216±0.01、0.203±0.01, 0.176±0.01 and 0.160±0.01, P<0.01).②Compared with those in the control (4.60±0.60 and 8.97±1.56), cells in S stage (13.06±0.83) and proliferation index (21.70±1.55) markedly increased by 10-7mol/L AVP (P<0.01, respectively). In the presence of 10-7mol/L Lacidipine, cells in S stage (8.84±0.80) and the proliferation index (15.46±1.84) were significantly lower than those in AVP group (P<0.01, respectively). ③The protein level of pERK1／2 in AVP group was significantly higher than that in control group (P<0.01). Lacidipine in the range of 10-9-10-6 mol/L attenuated the protein level of pERK1／2 of AVP group in a concentration dependent manner (P<0.01, respectively). CONCLUSION Lacidipine, which effectively inhibits the cell proliferation of CFs induced by AVP, may play some roles in the prevention and reversion of cardiac remodeling. The mechanism of the effect may be related to the phosphorylation of ERK1/2.

参考文献/References

［1］ Park JK, Fiebeler A, Muller DN,et al.Lacidipine inhibits adhesion molecule and oxidase expression independent of blood pressure reduction in angiotensioninduced vascular injury［J］. Hypertension,2002,39(2 pt 2):685-689.

［2］ Caqalinec M, Kyselovic J, Blaskova E,et al.Comparative study of the effects of lacidipine and enalapril on the left ventricular cardiomyocyte remodeling in spontaneously hypertensive rats［J］. J Cardiovasc Pharmacol,2006,47(4):561-570.

［3］ Moncrieff J，Lindsay MM，Dunn FG．Hypertensive heart disease and fibrosis［J］．Curr Opin Cardiol，2004，19(4)：326—331．

［4］ Verdecchia P, Angeli F. Reversal of left ventricular hypertrophy: what have recent trials taught us?［J］. Am J Cardiovasc Drugs, 2004, 4(6): 369-378.

［5］ Kuwahara F, Kai H, Tokuda K, et al. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation?［J］ Hypertension, 2004, 43(4): 739-745.

［6］ Xu Y, Hopfner RL, McNeill JR, et al. Vasopressin accelerates protein synthesis in neonatal rat cardiomyocytes［J］. Mol Cell Biochem, 1999, 195(1-2): 183-190.

［7］ Yang XD, Zhao LY, Zheng QS, et al. Effects of arginine vasopressin on growth of rat cardiac fibroblasts: role of V1 receptor［J］. J Cardiovasc Pharmacol, 2003, 42 (1): 132-135.

［8］ 尚福军，赵连友，郑强荪，等．钙调神经磷酸酶调控精氨酸升压素诱导大鼠心脏成纤维细胞增殖的作用［J］．高血压杂志，2004，l2(1)：58—61．

［9］ Kyselovic J,Krenek P,Wibo M,et al.Effects of amlodipine and lacidipine on cardiac remodlling and rennin production in saltloaded strokeprone hypertensive rats［J］. Br J Pharmacol,2001,134(7):1516-1522.

［10］Hecquet C, Lefevre G,Valtink M,et al.Activation and role of MAP kinasedependent pathways in retinal pingment epithelial cells:ERK and RPE cell proliferation［J］. Invest Ophthalmol Vis Sci,2002,43(9):3091-3098.

备注/Memo

备注/Memo:
收稿日期：2008-01-09.基金项目：陕西省自然科技基金资助项目(2004C2-21) 通讯作者：赵连友，教授，主要从事高血压发病的分子生物学机制研究Email：zhaolyfmmu@yahoo.com.cn 作者简介：陆小龙，医师，硕士生Email：luxlfmmu@yahoo.cn
更新日期/Last Update: